التفاصيل البيبلوغرافية
| العنوان: |
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. |
| المؤلفون: |
Schulte, Brian, Mohindra, Nisha, Milhem, Mohammed, Attia, Steven, Robinson, Steven, Monga, Varun, Hirbe, Angela C., Oppelt, Peter, Charlson, John, Helenowski, Irene, Abbinanti, Susan, Cehic, Rasima, Okuno, Scott, Van Tine, Brian A., Agulnik, Mark |
| المصدر: |
British Journal of Cancer; Aug2021, Vol. 125 Issue 4, p528-533, 6p |
| مصطلحات موضوعية: |
RESEARCH, TOPOTECAN, CLINICAL trials, HETEROCYCLIC compounds, OSTEOSARCOMA, ORAL drug administration, RESEARCH methodology, ANTINEOPLASTIC agents, PROGNOSIS, METASTASIS, MEDICAL cooperation, EVALUATION research, TREATMENT effectiveness, DRUG administration, COMPARATIVE studies, SULFONAMIDES, SARCOMA, LONGITUDINAL method |
| مستخلص: |
Background: Pazopanib is active in refractory soft-tissue sarcoma (STS) and significantly prolongs PFS. Prior studies of combinations of metronomic topotecan with pazopanib have indicated preclinical evidence of response in patients with sarcoma.Methods: This prospective, single arm, phase II study evaluated the efficacy of the combination of pazopanib with topotecan in patients with metastatic or unresectable non-adipocytic STS. Furthermore, it incorporated exploratory arms for osteosarcoma and liposarcoma. The primary endpoint was progression-free rate at 12 weeks in the non-adipocytic STS cohort.Results: 57.5% of patients in the non-adipocytic STS cohort were progression free at 12 weeks, which did not meet the primary endpoint of the study (66%). The exploratory osteosarcoma cohort exceeded previously established phase II trial comparator data benchmark of 12% with a PFR at 12 weeks of 69.55%. Treatment with the combination of pazopanib and topotecan was accompanied by a grade 3 or 4 toxicities in most patients.Conclusions: In this prospective trial in refractory metastatic or unresectable STS and osteosarcoma, the combination of pazopanib with topotecan did not meet its primary endpoint of progression-free rate at 12 weeks. The combination of pazopanib with topotecan was associated with a high degree of toxicity. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Cancer is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder